請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34962
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王勝仕(Sheng-Shih Wang) | |
dc.contributor.author | Chao-Long Chen | en |
dc.contributor.author | 陳昭隆 | zh_TW |
dc.date.accessioned | 2021-06-13T06:37:42Z | - |
dc.date.available | 2016-08-22 | |
dc.date.copyright | 2011-08-22 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-21 | |
dc.identifier.citation | 參考文獻
1. Ferri, C.P., et al., Global prevalence of dementia: a Delphi consensus study. Lancet, 2005. 366(9503): p. 2112-2117. 2. Minati, L., et al., Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. American Journal of Alzheimer's Disease and Other Dementias, 2009. 24(2): p. 95-121. 3. Clark, L.N., et al., Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proceedings of the National Academy of Sciences of the United States of America, 1998. 95(22): p. 13103-13107. 4. Wang, J.-Z., I. Grundke-Iqbal, and K. Iqbal, Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer's disease. Nat Med, 1996. 2(8): p. 871-875. 5. Martin, L., X. Latypova, and F. Terro, Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochemistry International, 2011. 58(4): p. 458-471. 6. Hardy, J. and D.J. Selkoe, Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 2002. 297(5580): p. 353-356. 7. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011. 7(3): p. 280-292. 8. Cummings, J.L., Alzheimer's Disease. N Engl J Med, 2004. 351(1): p. 56-67. 9. Selkoe, D.J., Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999. 399(6738): p. A23-A31. 10. Lichtenthaler, S.F., C. Haass, and H. Steiner, Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing. Journal of Neurochemistry, 2011. 117(5): p. 779-796. 11. Kehoe, P.G., S. Miners, and S. Love, Angiotensins in Alzheimer's disease – friend or foe? Trends in Neurosciences, 2009. 32(12): p. 619-628. 12. Furukawa, K., et al., Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature, 1996. 379(6560): p. 74-78. 13. Rockenstein, E., et al., High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels - Implications for the treatment of Alzheimer disease. Journal of Biological Chemistry, 2005. 280(38): p. 32957-32967. 14. Pardossi-Piquard, R., et al., Presenilin-dependent transcriptional control of the A beta-degrading enzyme neprilysin by intracellular domains of beta APP and APLP. Neuron, 2005. 46(4): p. 541-554. 15. Dumont, M., et al., Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. Journal of Neural Transmission, 2006. 113(9): p. 1225-1241. 16. Plant, L.D., et al., Amyloid [beta] peptide as a physiological modulator of neuronal [`]A'-type K+ current. Neurobiology of Aging, 2006. 27(11): p. 1673-1683. 17. Gotz, J., L.M. Ittner, and S. Kins, Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? Journal of Neurochemistry, 2006. 98(4): p. 993-1006. 18. Wirths, O., et al., Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiology of Aging, 2007. 28(11): p. 1689-1699. 19. Nicolakakis, N. and E. Hamel, Neurovascular function in Alzheimer's disease patients and experimental models. Journal of Cerebral Blood Flow & Metabolism, 2011. 31(6): p. 1354-1370. 20. Roychaudhuri, R., et al., Amyloid {beta}-Protein Assembly and Alzheimer Disease. The Journal of Biological Chemistry, 2009. 284(8): p. 4749-4753. 21. Postina, R., et al., A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model (vol 113, pg 1456, 2004). Journal of Clinical Investigation, 2004. 114(4): p. 598-598. 22. Elzbieta Kojro, F.F., The non-amyloidogenic pathway: structure and function of asecretases. Subcellular Biochemistry, 2005. 38: p. 105-127. 23. Hussain, I., et al., Identification of a novel aspartic protease (Asp 2) as beta-secretase. Molecular and Cellular Neuroscience, 1999. 14(6): p. 419-427. 24. Ghosh, A.K., et al., Structure-based design: Potent inhibitors of human brain memapsin 2 (beta-secretase). Journal of Medicinal Chemistry, 2001. 44(18): p. 2865-2868. 25. Kitazume, S., et al., Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proceedings of the National Academy of Sciences of the United States of America, 2001. 98(24): p. 13554-13559. 26. Wolfe, M.S., et al., Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 1999. 398(6727): p. 513-517. 27. Doerfler, P., M.S. Shearman, and R.M. Perlmutter, Presenilin-dependent gamma-secretase activity modulates thymocyte development. Proceedings of the National Academy of Sciences of the United States of America, 2001. 98(16): p. 9312-9317. 28. Hadland, B.K., et al., gamma-secretase inhibitors repress thymocyte development. Proceedings of the National Academy of Sciences of the United States of America, 2001. 98(13): p. 7487-7491. 29. Weggen, S., et al., A subset of NSAIDs lower amyloidogenic A beta 42 independently of cyclooxygenase activity. Nature, 2001. 414(6860): p. 212-216. 30. Yin, K.J., et al., Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. Journal of Neuroscience, 2006. 26(43): p. 10939-10948. 31. Tucker, H.M., et al., The plasmin system is induced by and degrades amyloid-beta aggregates. Journal of Neuroscience, 2000. 20(11): p. 3937-3946. 32. Mueller-Steiner, S., et al., Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron, 2006. 51(6): p. 703-714. 33. Qiu, W.Q., et al., Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. Journal of Biological Chemistry, 1997. 272(10): p. 6641-6646. 34. Qiu, W.Q., et al., Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid beta -Protein by Degradation. The Journal of Biological Chemistry, 1998. 273(49): p. 32730-32738. 35. Vekrellis, K., et al., Neurons Regulate Extracellular Levels of Amyloid beta -Protein via Proteolysis by Insulin-Degrading Enzyme. Journal of Neuroscience, 2000. 20(5): p. 1657-1665. 36. Leissring, M.A., et al., Enhanced Proteolysis of [beta]-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death. Neuron, 2003. 40(6): p. 1087-1093. 37. Bierer, L.M., et al., Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits. Journal of Neurochemistry, 1995. 64(2): p. 749-760. 38. Wolfe, M.S., Therapeutic strategies for Alzheimer's disease. Nature Reviews Drug Discovery, 2002. 1(11): p. 859-866. 39. Iwata, N., M. Higuchi, and T.C. Saido, Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacology & Therapeutics, 2005. 108(2): p. 129-148. 40. Yamada, T., et al., Selective Localization of Gelatinase-a, an Enzyme Degrading Beta-Amyloid Protein, in White-Matter Microglia and in Schwann-Cells. Acta Neuropathologica, 1995. 89(3): p. 199-203. 41. Roques, B.P., Cell surface metallopeptidases involved in blood pressure regulation: Structure, inhibition and clinical perspectives. Pathologie Biologie, 1998. 46(3): p. 191-200. 42. Anthony, J.T., R.E. Isaac, and C. David, The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays, 2001. 23(3): p. 261-269. 43. Miners, J.S., et al., A beta-degrading enzymes in Alzheimer's disease. Brain Pathology, 2008. 18(2): p. 240-252. 44. Xi Chen, S.D.Y., Mitochondrial Aβ A potential cause of metabolic dysfunction in Alzheimer's disease. 2006. 58(12): p. 686-694. 45. Van Nostrand, W.E. and M. Porter, Plasmin Cleavage of the Amyloid beta-Protein:Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activity. Biochemistry, 1999. 38(35): p. 11570-11576. 46. Serretti, A., P. Olgiati, and D. De Ronchi, Genetics of Alzheimer's disease. A rapidly evolving field. Journal of Alzheimers Disease, 2007. 12(1): p. 73-92. 47. Mort, J.S. and D.J. Buttle, Cathepsin B. International Journal of Biochemistry & Cell Biology, 1997. 29(5): p. 715-720. 48. Turner, A.J. and N.N. Nalivaeva, New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Neuroinflammation in Neuronal Death and Repair, 2007. 82: p. 113-135. 49. Sun, X., et al., Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-β peptides. European Journal of Pharmacology, 2008. 588(1): p. 18-25. 50. Turner, A.J., Neprilysin. In A. J. Barrett, N. D. Rawlings, & J. F. Woessner (Eds.). handbook of proteolysis enzymes, second edition, vol. 1, Ch. 108, 2004: p. 419-426. 51. Barnes, K., S. Doherty, and A.J. Turner, Endopeptidase-24.11 Is the Integral Membrane Peptidase Initiating Degradation of Somatostatin in the Hippocampus. Journal of Neurochemistry, 1995. 64(4): p. 1826-1832. 52. Sakurada, C., et al., Degradation of nociceptin (orphanin FQ) by mouse spinal cord synaptic membranes is triggered by endopeptidase-24.11: an in vitro and in vivo study. Biochemical Pharmacology, 2002. 64(8): p. 1293-1303. 53. Lafrance, M.H., et al., Role of Glycosylation in Transport and Enzymatic-Activity of Neutral Endopeptidase-24.11. Biochemical Journal, 1994. 302: p. 451-454. 54. Dragovic, T., et al., Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. Anticancer Research, 1997. 17(5A): p. 3233-3238. 55. McIntosh, G.G., et al., NCL-CD10?70: A New Monoclonal Antibody Recognizing CD10 in Paraffin-Embedded Tissue. American Journal of Pathology, 1999. 154(1): p. 77-82. 56. YUKIHIKO SATO, F.I., YuJI HINODA, YASUO OHE, NAOAKI NAKAGAWA, RYUZO UEDA~ AKIRA YACHI, and KO~ZOH IMA, Expression of CDlO/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. Journal of Gastroenterology, 1996. 31: p. 12-17. 57. Shipp, M.A., et al., CD10/Neutral Endopeptidase 24.11 Hydrolyzes Bombesin-Like Peptides and Regulates the Growth of Small Cell Carcinomas of the Lung. Proceedings of the National Academy of Sciences of the United States of America, 1991. 88(23): p. 10662-10666. 58. Lu, B., et al., Neutral endopeptidase modulation of septic shock. Journal of Experimental Medicine, 1995. 181(6): p. 2271-2275. 59. Huang, J., et al., Estrogen regulates neprilysin activity in rat brain. Neuroscience Letters, 2004. 367(1): p. 85-87. 60. Erdos, E.G. and R.A. Skidgel, The Angiotensin-I-Converting Enzyme. Laboratory Investigation, 1987. 56(4): p. 345-348. 61. Reid, I.A., Interactions between Ang-Ii, Sympathetic Nervous-System, and Baroreceptor Reflexes in Regulation of Blood-Pressure. American Journal of Physiology, 1992. 262(6): p. E763-E778. 62. McFarlane, S.I., A. Kumar, and J.R. Sowers, Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. American Journal of Cardiology, 2003. 91(12): p. 30h-37h. 63. Oba, R., et al., The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. European Journal of Neuroscience, 2005. 21(3): p. 733-740. 64. Kurochkin, I.V. and S. Goto, Alzheimers Beta-Amyloid Peptide Specifically Interacts with and Is Degraded by Insulin Degrading Enzyme. Febs Letters, 1994. 345(1): p. 33-37. 65. Mukherjee, A., et al., Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. Journal of Neuroscience, 2000. 20(23): p. 8745-8749. 66. Kirschner, R.J. and A.L. Goldberg, A High Molecular-Weight Metalloendoprotease from the Cytosol of Mammalian-Cells. Journal of Biological Chemistry, 1983. 258(2): p. 967-976. 67. Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., Yhu, S., McInnis, M. G., Go, R. C., Vekrellis, K., et al., Evidence for Genetic Linkage of Alzheimer's Disease to Chromosome 10q. Science, 2000. 290: p. 2302-2303. 68. Wiltshire, S., Hattersley, A.T., Hitman, G.A., Walker, M., Levy, J.C., Sampson, M., O'Rahilly, S., Frayling, T.M., Bell, J.I., Lathrop, G.M. et al, A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. The American Journal of Human Genetics, 2001. 69: p. 553-569. 69. Farris, W., et al., Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003. 100(7): p. 4162-4167. 70. Miller, B.C., et al., Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003. 100(10): p. 6221-6226. 71. Kuusisto, J., et al., Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. British Medical Journal, 1997. 315(7115): p. 1045-1049. 72. Ott, A., et al., Association of diabetes mellitus and dementia: The Rotterdam study. Diabetologia, 1996. 39(11): p. 1392-1397. 73. Chesneau, V. and M.R. Rosner, Functional Human Insulin-Degrading Enzyme Can Be Expressed in Bacteria. Protein Expression and Purification, 2000. 19(1): p. 91-98. 74. Misbin, R.I. and E.C. Almira, Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14- and B26-[125I]monoiodoinsulin. Diabetes, 1989. 38(2): p. 152-158. 75. Mirsky, I.A., G. Perisutti, and D. Diengott, Effect of insulinase-inhibitor on destruction of insulin by intact mouse. Proceedings of the Society for Experimental Biology and Medicine, 1955. 88(1): p. 76-78. 76. Clausen, T., C. Southan, and M. Ehrmann, The HtrA family of proteases: Implications for protein composition and cell fate. Molecular Cell, 2002. 10(3): p. 443-455. 77. Barnes, K. and A.J. Turner, Endothelin converting enzyme is located on alpha-actin filaments in smooth muscle cells. Cardiovascular Research, 1999. 42(3): p. 814-822. 78. Valdenaire, O., et al., A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter - Molecular cloning and characterization. European Journal of Biochemistry, 1999. 264(2): p. 341-349. 79. Lewis, J., et al., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001. 293(5534): p. 1487-1491. 80. Eckman, E.A., et al., Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. Journal of Biological Chemistry, 2003. 278(4): p. 2081-2084. 81. Melchor, J.P., R. Pawlak, and S. Strickland, The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-{beta} (A{beta}) Degradation and Inhibits A{beta}-Induced Neurodegeneration. J. Neurosci., 2003. 23(26): p. 8867-8871. 82. Tucker, H.M., et al., Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. Neuroscience Letters, 2004. 368(3): p. 285-289. 83. Backstrom, J.R., et al., Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-beta Peptide (1-40). Journal of Neuroscience, 1996. 16(24): p. 7910-7919. 84. Roher, A.E., et al., Proteolysis of A[beta] Peptide from Alzheimer Disease Brain by Gelatinase A. Biochemical and Biophysical Research Communications, 1994. 205(3): p. 1755-1761. 85. James Scott, M., et al., A beta-Degrading Enzymes in Alzheimer's Disease. Brain Pathology, 2008. 18(2): p. 240-252. 86. Kenworthy, A.K., Imaging Protein-Protein Interactions Using Fluorescence Resonance Energy Transfer Microscopy. Methods, 2001. 24(3): p. 289-296. 87. Gordon, G.W., et al., Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy. Biophysical Journal, 1998. 74(5): p. 2702-2713. 88. Erickson, J.W., R. Mittal, and R.A. Cerione, Use of Resonance Energy-Transfer to Determine the Proximity of the Guanine-Nucleotide-Binding Site of Transducin Relative to a Conformationally-Sensitive Site on the Gamma-Subunit of the Cyclic-Gmp Phosphodiesterase. Biochemistry, 1995. 34(27): p. 8693-8700. 89. Moens, P.D.J., D.J. Yee, and C.G. Dosremedios, Determination of the Radial Coordinate of Cys-374 in F-Actin Using Fluorescence Resonance Energy-Transfer Spectroscopy - Effect of Phalloidin on Polymer Assembly. Biochemistry, 1994. 33(44): p. 13102-13108. 90. Ha, T., et al., Probing the interaction between two single molecules: Fluorescence resonance energy transfer between a single donor and a single acceptor. Proceedings of the National Academy of Sciences of the United States of America, 1996. 93(13): p. 6264-6268. 91. Woolley, A.T. and R.A. Mathies, Ultra-High-Speed DNA-Sequencing Using Capillary Electrophoresis Chips. Analytical Chemistry, 1995. 67(20): p. 3676-3680. 92. Eve-Isabelle Pecheur, I.M., Jean-Marie Ruysschaert, Alain Bienvenue, and Dick Hoekstra, Membrane Fusion Induced by 11-mer Anionic and Cationic Peptides: A Structure−Function Study. Biochemistry, 1998. 37(8): p. 2361-2371. 93. Morrison, L.E., Time-Resolved Detection of Energy-Transfer - Theory and Application to Immunoassays. Analytical Biochemistry, 1988. 174(1): p. 101-120. 94. Rhee, S.S. and D.H. Burke, Tris(2-carboxyethyl)phosphine stabilization of RNA: comparison with dithiothreitol for use with nucleic acid and thiophosphoryl chemistry. Analytical Biochemistry, 2004. 325(1): p. 137-143. 95. Richard P. Haugland, M.T.Z.S., Iain Johnson, Aaron Basey, The Handbook - A guid to fluorescenct probes and labeling technologies. 2005. 96. Dequaire, M., C. Degrand, and B. Limoges, An Electrochemical Metalloimmunoassay Based on a Colloidal Gold Label. Analytical Chemistry, 2000. 72(22): p. 5521-5528. 97. Wang, G.T., et al., Design and synthesis of new fluorogenic HIV protease substrates based on resonance energy transfer. Tetrahedron Letters, 1990. 31(45): p. 6493-6496. 98. Chen, P.-T., et al., A highly sensitive peptide substrate for detecting two A[beta]-degrading enzymes: Neprilysin and insulin-degrading enzyme. Journal of Neuroscience Methods, 2010. 190(1): p. 57-62. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34962 | - |
dc.description.abstract | 摘要
類澱粉b蛋白質(Ab)是一種生理上的胜肽,由類澱粉前驅蛋白(APP)經一系列代謝途徑所生成。釋出胞外的Ab會被許多的內切胜肽酶進行降解代謝,若在腦中的生成與代謝之失衡,則會導致聚集的產生,此為阿茲海默症的成因。阿茲海默症為一種神經退化性疾病,由此可見其發病機制中,Ab的生成是個十分重要的因素,清除新生成的Ab胜肽被認為是治療阿茲海默症可行的策略之一,而可清除Ab胜肽的酵素計有腦啡肽酶 (neprilysin、NEP)、胰島素降解酶 (insulin degrading enzyme、IDE)、內皮素轉化酶 (endothelin converting enzyme、ECE-1)、血管緊張素轉換酶 (angiotensin-converting enzyme、ACE)、血纖維蛋白溶酶(plasmin)、和基質金屬蛋白酶 (matrix metalloproteinase、MMPs)等。 於此研究中,我們合成淬滅螢光之胜肽受質來偵測各種酵素的活性及靈敏度,最初所採用的胜肽是Ab上第十二個胺基酸殘基至第十八個胺基酸殘基,且在最後一個胺基酸殘基後再接上一個半胱胺酸(cysteine, Cys)。一螢光分子連接在胜肽的C端,其發出的螢光會被存在於N端半胱氨酸側鏈上的一淬滅分子所消滅,此基質命名為qf-Ab(12-18)C,當此胜肽基質被酵素水解後,便會放出螢光。 本研究發現共有四種酵素可水解此基質qf-Ab(12-18)C,分別是NEP、ACE、ECE-1與IDE,前兩者活性較高,後兩者反應性較小,沒有明顯的專一性。然後我們嘗試把原本的7個胺基酸殘基的後面兩個殘基改成丙胺酸,經由一樣的合成步驟,得到的新基質命名為qf-Ab(12-16)AAC。本研究發現只剩前兩者NEP與ACE對此基質有活性。明顯地,相較於原本的qf-Ab(12-18)C,qf-Ab(12-16)AAC雖然無法用來偵測單一酵素的活性,但其專一性也有所提升。 此外,在使用細胞進行檢測之方面,有研究指出qf-Ab(1-7)C只能被NEP及IDE水解,而吾人的qf-Ab(12-16)AAC,只能被NEP及ACE水解。利用前述特性,將可建立一互相比較的快速藥物篩檢系統,用以篩檢出對於NEP、ACE、或IDE有增加活性或抑制效果之藥物。 關鍵字:類澱粉b蛋白質、Ab降解酶、螢光共振能量轉移。 | zh_TW |
dc.description.abstract | Abstract
Amyloid-b (Ab) is a physiological peptide, which is produced from amyloid precursor protein (APP) by sequential cleavages, and then released into the extracellular spaces. The released Ab undergoes proteolytic degradation by multiple endopeptidases. The imbalance between the production and catabolism of Ab in the brain results in the accumulation of Ab leading to Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative disease, and Ab in Alzheimer’s disease plays a pivotal role in the pathogenesis of the disease. Reduction of Ab production is considered a feasible way in the therapeutics for Alzheimer’s disease. The enzymes that are capable of hydrolyzing Ab include neprilysin (NEP), insulin degrading enzyme (IDE), endothelin converting enzyme (ECE-1), angiotensin-converting enzyme (ACE), plasmin and matrix metalloproteinase (MMPs). In this study, we synthesized a quenched fluorogenic peptide substrate whose seven-residue sequence was adopted from the twelfth to eighteenth residues of Ab peptide with a cystenine residue (Cys) added at its C-terminal. The fluorescence emission contributed by the fluorophore attached to the C-terminal Cys residue was quenched by the presence of the quencher linked to the N-terminus of the peptide. The synthetic peptide substrate mentioned above was named as qf-Ab(12-18)C. The fluorescence was emitted when this peptide substrate was degraded by enzymes. We observed in our study that four enzymes exhibit activity toward our synthetic peptide substrate qf-Ab(12-18)C, including NEP, ACE, IDE, and ECE-1. Our results showed that the former two have higher activities, whereas the latter two have lower activities, suggesting that qf-Ab(12-18)C lacks a good enzyme specificity. Next, we made an attempt to modify the sequence of the peptide substrate, changing the last two residues from luecine and valine to two alanine. Following the same method mentioned previously, a new peptide substrate was obtained and called qf-Ab(12-16)AAC. Only two enzymes, including NEP and ACE, were found to be effective in hydrolyzing the new substrate qf-Ab(12-16)AAC. It is evident that the new peptide substrate qf-Ab(12-16)AAC possesses a superior enzyme specificity over qf-Ab(12-18)C. Moreover, the cell-based assay was performed in our study. Our previous investigation showed that qf-Ab(1-7)C can be hydrolyzed by only two enzymes, NEP and IDE. However, we found in this work that NEP and ACE are able to hydrolyze qf-Ab(12-16)AAC. We believe the combination of these two different peptide substrates allows us to develop a fluorescence-based platform for detecting the chemicals which can enhance or reduce the activity of important Ab-degarding enzymes. Key words:Amyloid-b, Ab-degrading enzymes, neprilysin, angiotensin-converting enzyme, insulin degrading enzyme, fluorescence resonance energy transfer (FRET). | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:37:42Z (GMT). No. of bitstreams: 1 ntu-100-R98524080-1.pdf: 1545778 bytes, checksum: e24bdd81b5b5e9a64b2b438aa481347b (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
誌謝 II 摘要 III Abstract V 縮寫表 VII 目錄 VIII 圖目錄 XI 表目錄 XIV 第一章 緒論 1 第二章 文獻回顧 3 2-1 阿茲海默症簡介 3 2-1-1 類澱粉前驅蛋白(amyloid precursor protein) 9 2-1-2 類澱粉b蛋白質 11 2-1-3 阿茲海默症的治療策略 11 2-2 類澱粉貝塔蛋白降解酵素 15 2-2-1 Neprilysin 18 2-2-2 Angiotensin-converting enzyme (ACE) 21 2-2-3 Insulin-degrading enzyme(IDE) 22 2-2-4 Endothelin-converting enzyme-1 (ECE-1) 23 2-2-5 Plasmin 23 2-2-6 Matrix metalloproteinases (MMPs) 24 2-3固相胜肽合成法介紹 25 2-4螢光共振能量轉移(Fluorescence Resonance Energy Transfer, FRET) 28 2-5螢光探針分子簡介 31 2-5-1 Thiol-reactive dye 31 2-5-2 Alexa Fluor 350 C5-Maleimide 32 2-5-3 The Alexa Fluor Dye Series 34 2-5-4 Amine-reactive dye 35 2-5-5 4-((4-(dimethylamino)phenyl)azo)benzoic acid, succinimidyl ester (Dabcyl) 36 第三章 研究動機 37 第四章 實驗裝置、藥品與步驟 38 4-1實驗藥品 38 4-1-1 水 38 4-1-2 化學藥品 38 4-2實驗儀器 41 4-3 實驗步驟 42 4-3-1類澱粉b蛋白質片段Ab(12-18)C以及Ab(12-16)AAC的合成、純化、與鑑定 42 4-3-2 胜肽Ab(12-18)C、Ab(12-16)AAC和螢光供體Alexa-350之合成、純化以及鑑定 43 4-3-3 Alexa350-Ab(12-18)C及Alexa350-Ab(12-16)AAC和quencher之合成、純化以及鑑定 45 4-3-4 螢光光譜分析 46 4-3-5 各種類澱粉蛋白降解酵素對受質Ab(12-18)C及qf-Ab(12-16)AAC之活性測試 46 4-3-6各種類澱粉蛋白降解酵素對受質Ab(12-18)C及qf-Ab(12-16)AAC在長時間的螢光分析 47 4-3-7 各酵素對受質qf-Ab(12-18)C及qf-Ab(12-16)AAC螢光檢測之靈敏度 48 4-3-8 SH-SY5Y細胞之培養 49 4-3-9 在細胞上進行受質qf-Ab(12-18)C及qf-Ab(12-16)AAC之螢光分析 50 第五章 結果與討論 52 5-1 胜肽基質qf-Ab(12-18)C 與qf-Ab(12-16)AAC之合成與身分鑑定 52 5-1-1 類澱粉貝塔片段Ab(12-18)C 與Ab(12-16)AAC之合成與身分鑑定 53 5-1-2 Alexa-350-Ab(12-18)C 與Alexa-350-Ab(12-16)AAC之合成與身分鑑定 58 5-1-3 qf-Ab(12-18)C與qf-Ab(12-16)AAC之合成與身分鑑定 64 5-2 探討各酵素與受質qf-Ab(12-18)C、qf-Ab(12-16)AAC之專一性檢測 72 5-3各酵素對受質qf-Ab(12-18)C以及qf-Ab(12-16)AAC螢光檢測之靈敏度探討 81 5-4 實驗結論與未來展望 85 參考文獻 87 圖目錄 圖2-1-1 Tau蛋白纖維化的示意圖 5 圖2-1-2 阿茲海默症導致認知障礙的假說路徑 7 圖2-1-3 Amyloid cascade想像圖 8 圖2-1-4 類澱粉前驅蛋白之代謝途徑圖 10 圖2-1-5 類澱粉b蛋白質的胺基酸序列 11 圖2-1-6 b-secretase的抑制劑 13 圖2-1-7 | |
dc.language.iso | zh-TW | |
dc.title | 探討胜肽基質序列之改變對靈敏螢光分析中酵素專一性之影響 | zh_TW |
dc.title | Examining the Effects of Modulation of Peptide Substrate Sequence on the Enzyme Specificity in the Sensitive fluoresence Assay | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳佩燁,胡朝榮,林達顯,楊定一 | |
dc.subject.keyword | 類澱粉beta蛋白質,A-beta降解酶,螢光共振能量轉移, | zh_TW |
dc.subject.keyword | Amyloid-beta,A-beta-degrading enzymes,neprilysin,angiotensin-converting enzyme,insulin degrading enzyme,fluorescence resonance energy transfer, | en |
dc.relation.page | 94 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-21 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.51 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。